Bristol-Myers Squibb Company announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).
Aveo Oncology’s Phase III study of tivozanib for highly refractory advanced or metastatic renal cell carcinoma (RCC) met the primary endpoint of demonstrating a statistically significant benefit in PFS.
An Opdivo-Yervoy combo yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma than standard of care sunitinib.
Merck KGaA said the immunotherapy Bavencio, jointly developed with Pfizer Inc., delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.
Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.
Genentech announced results from the positive Phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
Amgen Inc. and Allergan plc. announced that the European Commission granted marketing authorization for Mvasi (biosimilar bevacizumab).
Merck & Co. and development partner Eisai Co. snagged Breakthrough Therapy Designation from the FDA for a combo renal cell carcinoma (RCC) treatment.
Merck KGaA and Pfizer Inc. announced that the U.S. FDA granted Breakthrough Therapy Designation for avelumab in combination with Inlyta (axitinib) treatment-naïve patients with advanced renal cell carcinoma.
Argos Therapeutics announced positive interim data for the company’s kidney cancer drug Rocapuldencel-T from a Phase III clinical trial.